|Last Price||Today's Change||52-Week Range||Trading Volume|
|41.06||-0.92 (-2.19%)||30.05 - 52.33||386.1 thousand|
Market data as of 11:47AM 12/01/15. Quotes are delayed by at least 15 min.
Seattle Genetics Initiates Phase 1/2 Clinical Trial of SGN-CD33A (Vadastuximab Talirine) Before or After Allogeneic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia
11/23/2015 8:00 AM ET
Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs
11/05/2015 4:02 PM ET